This article is more than 5 years old. Information may no longer be current.

Ozurdex for retinal vein occlusion approved in China

Issue: November 2017

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The Chinese Food and Drug Administration has approved Ozurdex to treat adults with macular edema after branch retinal vein occlusion or central retinal vein occlusion, according to a press release from Allergan.

Ozurdex (dexamethasone intravitreal implant 0.7 mg) is the first intravitreal injection approved for RVO in China, where there are approximately 7.4 million RVO patients, the release said.

“The approval of Ozurdex underscores our commitment to bring more innovative eye care solutions to tackle unmet medical needs in China. Coming next, Allergan China will be accelerating access to Ozurdex for Chinese hospitals — and more importantly to Chinese patients,” Shirley Zhao, Allergan China president, said in the release.